Equities Analysts Set Expectations for DNTH FY2025 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Investment analysts at Lifesci Capital raised their FY2025 earnings per share (EPS) estimates for shares of Dianthus Therapeutics in a research note issued to investors on Wednesday, March 12th. Lifesci Capital analyst R. Katkhuda now expects that the company will post earnings per share of ($2.50) for the year, up from their prior estimate of ($2.53). The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.

Other equities analysts also recently issued reports about the company. Guggenheim reaffirmed a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Wedbush reissued an “outperform” rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday. Finally, TD Cowen began coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating for the company. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Dianthus Therapeutics has a consensus rating of “Buy” and a consensus target price of $52.14.

Dianthus Therapeutics Trading Up 0.2 %

Shares of NASDAQ:DNTH opened at $21.33 on Friday. The business has a 50-day moving average price of $22.54 and a 200 day moving average price of $24.83. Dianthus Therapeutics has a 12-month low of $18.13 and a 12-month high of $33.77. The company has a market capitalization of $631.30 million, a price-to-earnings ratio of -8.53 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The firm had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC lifted its stake in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after buying an additional 1,124 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth approximately $26,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth approximately $33,000. KBC Group NV purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth approximately $35,000. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth approximately $59,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.